Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVO CervoMed	$6.99 -1.0%	$8.54	$1.80 ▼ $22.57	$61.44M	-0.73	1.34 million shs	52,817 shs
FHTX Foghorn Therapeutics	$4.75 -0.8%	$4.19	$2.94 ▼ $10.25	$267M	3.04	142,867 shs	200,267 shs
IMMP Prima BioMed	$1.61 -3.0%	$1.79	$1.32 ▼ $2.80	$242.43M	1.76	207,481 shs	135,546 shs
LFCR Lifecore Biomedical	$6.71 -1.5%	$6.65	$3.68 ▼ $7.99	$252.14M	0.65	239,387 shs	75,762 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVO CervoMed	-2.75%	-8.55%	-19.59%	-24.65%	-62.14%
FHTX Foghorn Therapeutics	+9.11%	+3.46%	+8.13%	+7.88%	-16.70%
IMMP Prima BioMed	-2.92%	-10.75%	-18.23%	-13.09%	-38.29%
LFCR Lifecore Biomedical	+2.10%	-0.73%	-1.16%	+2.41%	+32.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVO CervoMed	3.3861 of 5 stars	3.4	5.0	3.2	1.7	0.6
FHTX Foghorn Therapeutics	1.7815 of 5 stars	3.6	2.0	0.0	1.7	0.6
IMMP Prima BioMed	1.0737 of 5 stars	3.5	1.0	1.0	0.0	0.0
LFCR Lifecore Biomedical	1.8101 of 5 stars	2.3	3.0	0.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVO CervoMed	2.89	Moderate Buy	$27.63	295.21% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	155.26% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	334.78% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	19.23% Upside

Current Analyst Ratings Breakdown

Latest CRVO, IMMP, LFCR, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/12/2025	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00
4/23/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVO CervoMed	$9.74M	6.24	N/A	N/A	$4.50 per share	1.55
FHTX Foghorn Therapeutics	$22.60M	11.72	N/A	N/A	($0.82) per share	-5.79
IMMP Prima BioMed	$5.14M	45.74	N/A	N/A	$1.05 per share	1.53
LFCR Lifecore Biomedical	$128.26M	1.94	N/A	N/A	$0.37 per share	18.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVO CervoMed	-$16.29M	-$2.18	N/A	N/A	N/A	-200.57%	-44.07%	-40.65%	8/8/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-35.90%	-551.09%	-13.89%	8/15/2025 (Estimated)

Latest CRVO, IMMP, LFCR, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/12/2025	Q1 2025	CRVO CervoMed	-$0.60	-$0.56	+$0.04	-$0.56	$1.70 million	$1.92 million
4/3/2025	Q3 2025	LFCR Lifecore Biomedical	-$0.14	-$0.19	-$0.05	-$0.47	$33.23 million	$35.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVO CervoMed	N/A	9.78	9.78
FHTX Foghorn Therapeutics	N/A	3.16	3.16
IMMP Prima BioMed	N/A	18.86	N/A
LFCR Lifecore Biomedical	66.36	2.71	1.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVO CervoMed	25.15%
FHTX Foghorn Therapeutics	61.55%
IMMP Prima BioMed	2.32%
LFCR Lifecore Biomedical	83.36%

Insider Ownership

Company	Insider Ownership
CRVO CervoMed	35.40%
FHTX Foghorn Therapeutics	7.58%
IMMP Prima BioMed	3.07%
LFCR Lifecore Biomedical	32.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVO CervoMed	4	8.70 million	5.62 million	Not Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	25.10 million	Optionable

CRVO, IMMP, LFCR, and FHTX Headlines

Recent News About These Companies

Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy

June 18 at 5:30 AM | kalkinemedia.com

Lifecore Biomedical: Inflecting Financials Over Next 3 Years

June 18 at 5:30 AM | seekingalpha.com

Lifecore Biomedical signs new 10-year commercial manufacturing and supply agreement

June 17 at 7:28 PM | msn.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect

June 17 at 10:00 AM | accessnewswire.com

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

June 17 at 7:00 AM | globenewswire.com

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

June 15 at 10:00 AM | accessnewswire.com

Lifecore Receives Full Payment Early For $17 Mln Equipment Sale

June 14, 2025 | nasdaq.com

Lifecore Biomedical, Inc.: Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

June 12, 2025 | finanznachrichten.de

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation

June 12, 2025 | accessnewswire.com

Lifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment sale

June 12, 2025 | msn.com

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

June 12, 2025 | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation

June 10, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out

June 8, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation

June 5, 2025 | accessnewswire.com

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

June 3, 2025 | accessnewswire.com

Deutsche Bank AG Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

June 3, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Shareholders to Inquire about Securities Investigation

June 1, 2025 | accessnewswire.com

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by BNP Paribas Financial Markets

June 1, 2025 | marketbeat.com

Insider Selling: Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Sells 96,137 Shares of Stock

May 30, 2025 | marketbeat.com

Aron R. English Sells 150,419 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock

May 30, 2025 | marketbeat.com

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Aron R. English Sells 1,139,504 Shares

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO, IMMP, LFCR, and FHTX Company Descriptions

CervoMed NASDAQ:CRVO

$6.99 -0.07 (-0.99%)

Closing price 04:00 PM Eastern

Extended Trading

$7.13 +0.14 (+1.95%)

As of 07:55 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Foghorn Therapeutics NASDAQ:FHTX

$4.75 -0.04 (-0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$4.76 +0.01 (+0.19%)

As of 04:34 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Prima BioMed NASDAQ:IMMP

$1.61 -0.05 (-3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$1.64 +0.03 (+1.86%)

As of 07:26 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Lifecore Biomedical NASDAQ:LFCR

$6.71 -0.10 (-1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$6.71 0.00 (0.00%)

As of 04:04 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time